---
title: "STAT+: Kyverna’s cell therapy shows lasting autoimmune benefit"
description: "Kyverna Therapeutics is one step closer to launching the first cell therapy for an autoimmune disease, with new data in hand showing many patients remained off of other therapies a…"
author: "Meghana Keshavan"
section: health
published: 2026-10-06T13:33:00.177031+00:00
canonical: https://valorandventures.media/article/eb44ef2b-2ccc-4fbf-8c40-30bd1c195ea9
publisher: "Valor & Ventures Media"
source: "STAT News"
source_url: https://www.statnews.com/2026/09/24/biotech-news-kyverna-cell-therapy-shows-lasting-autoimmune-benefit/?utm_campaign=rss
access: free
---

# STAT+: Kyverna’s cell therapy shows lasting autoimmune benefit

*Kyverna Therapeutics is one step closer to launching the first cell therapy for an autoimmune disease, with new data in hand showing many patients remained off of other therapies a…*

## Article

---
Meghana Keshavan · STAT News · Photo: Courtesy Tslil Ast Mootha Laboratory

---

Originally published by STAT News: https://www.statnews.com/2026/09/24/biotech-news-kyverna-cell-therapy-shows-lasting-autoimmune-benefit/?utm_campaign=rss